Private investors agreed to spend $85 million to purchase the company's stock.
March S&P 500 futures (ESH23) are trending down -0.45% this morning after three major U.S. benchmark indices ended the regular session higher, powered by a rebound in mega-cap growth stocks as U.S. unemployment...
ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.
March S&P 500 futures (ESH23) are trending down -0.10% this morning after three major U.S. benchmark indices rallied on Wednesday, notching their biggest one-day percentage gains this month as upbeat corporate...
AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.
Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.
The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma.
NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.
GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.
The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.